McKesson Corporation vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? McKesson Corporation trades at $937.1 (market cap $108.46B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.16 (market cap $3.80B). The key difference: McKesson Corporation is far larger — about 28.5× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and McKesson Corporation pays a 0.4% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| MCK | VNQI | |
|---|---|---|
Market Cap | $108.46B | $3.80B |
Volume | 712,607 | 277,049 |
Sector | Health | — |
52-Week High | $995.69 | $50.76 |
52-Week Low | $725.17 | $41.81 |
Typical Hold Time | 74 Days | 95 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
VNQI trades at $42.15, up 0.81% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF focuses on international real estate, offering diversification and a higher dividend yield than some peers, but key financial ratios are not disclosed in the provided data. Recent news highlights a significant drop in short interest and comparisons with competing real estate ETFs.
The outlook remains cautious due to weak technical momentum and global real estate market uncertainties. Opportunities include international diversification and income from dividends, but risks involve currency fluctuations, economic cycles abroad, and underperformance versus U.S. real estate. Investors should weigh the bearish technicals against long-term diversification benefits.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →